Recruiting Pancreatic Cancer Studies in San Francisco
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in...
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment....
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRIN...
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monoth...
A Phase II Nationwide, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distan...
About Pancreatic Cancer Clinical Trials in San Francisco
Pancreatic cancer begins in the tissues of the pancreas and is often diagnosed at an advanced stage. It is one of the most challenging cancers to treat. Clinical trials are actively investigating new approaches including immunotherapy and combination regimens.
There are currently 5 pancreatic cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 1,300 participants. Research is being sponsored by Bristol-Myers Squibb, Revolution Medicines, Inc., Genentech, Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pancreatic Cancer Clinical Trials in San Francisco — FAQ
Are there pancreatic cancer clinical trials in San Francisco?
Yes, there are 5 pancreatic cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in San Francisco?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.
Are clinical trials in San Francisco free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.
What pancreatic cancer treatments are being tested?
The 5 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for pancreatic cancer.
Data updated March 2, 2026 from ClinicalTrials.gov